Please login to the form below

Not currently logged in
Email:
Password:

primary hyperoxaluria type 1

This page shows the latest primary hyperoxaluria type 1 news and features for those working in and with pharma, biotech and healthcare.

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Lumasiran hits its objectives in the 20-patient phase 3 trial, which involved patients aged six and over with primary hyperoxaluria type 1 (PH1), a life-threatening but ultra-rare condition ... type 2 form (PH2) of the disease, which is caused by a

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...

Infographics